0 results for 'Novo Nordisk'
Ozempic MDL Expands to Include New Drugs, but Not New Injuries
"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly become procedurally and substantively unwieldy,” the Judicial Panel of Multidistrict Litigation ruled.Five Noteworthy Litigation Trends of 2024—and What to Watch in 2025
With the potential to redefine key areas of the law, here are the five most interesting litigation hotspots spotted by Law.com Radar in 2024.Litigation Surge: Drugmakers Launch Flood of Suits to Halt Generics
At least 29 patent suits were filed in the District of New Jersey in November, reflecting a jump from the rate of 18 suits per month in the period from December 2023 to November 2024. The multitude of suits include many that stem from generic drugmakers' plans to sell lower-priced versions of recognized pharmaceutical products.'Big Law Had Become Too Woke': Why Bill Barr Moved On
The former U.S. Attorney General headlined the Government Investigations & Civil Litigation Institute conference in Fort Lauderdale, Florida.Holland & Knight, Akin, Crowell, Barnes and Day Pitney Add to DC Practices
In the latest round of lateral hiring in D.C., Holland & Knight, Day Pitney, Akin Gump, Barnes and Crowell announced new attorney hires this week.View more book results for the query "Novo Nordisk"
Judge Shuts Down Efforts to Expand Scope of Discovery in Ozempic MDL
Judge Karen Marston held that, despite plaintiffs' arguments to the contrary, marketing discovery is not relevant to the broad legal issues the court has prioritized for early resolution.Ozempic Plaintiffs Push for Marketing Discovery After MDL Judge Imposes Limits
"These are not case-specific issues," the plaintiffs contended. "The marketing was national in scale and magnitude, and everything that occurred with regard to these drugs over the last several years is in some way tethered to the marketing."4 Law Firms Back Texas AG Suit on Insulin Price-Gouging Allegations
The state alleges this insulin pricing scheme violates the Texas Deceptive Trade Practices Act, constitutes unjust enrichment, and represents an unlawful civil conspiracy.FTC Takes Legal Action Against Three Largest PBMs Over High Insulin Prices
"Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug costs have skyrocketed over the past decade thanks in part to powerful PBMs and their greed," said Rahul Rao, deputy director of the FTC's Bureau of Competition.Trending Stories
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
Why Embracing Change Is Essential for Your Legal Department
Brought to you by DiliTrust
Download Now
International Export and Trade Assistance State Law Survey
Brought to you by LexisNexis®
Download Now
How This Personal Injury Firm Reduced Client Intake Time by 80%
Brought to you by PracticePanther
Download Now
The Hidden Cost of Bad Reviews: Why Law Firms & Attorneys Can't Afford a Damaged Online Reputation
Brought to you by Erase.com
Download Now